Patients
myelosuppression
ONCOLOGY, OESOPHAGEAL SQUAMOUS CELL CARCINOMA, RECURRENCE
This study was a single-arm, phase Ib/II trial conducted in a single institute in China. Eligibility was defined as follows: 1) previously radically treated (surgery or CCRT), histologically confirmed local or regional recurrence esophageal squamous cell carcinoma; 2) at least one measurable lesion; 3) suitable for the design of this study, according to the researchers’ evaluation (if radiotherapy was included in the previous treatment, at least 8 months had passed since the end of the previous radiotherapy before enrollment); 4) age 18–75 years, who could understand and sign the content and risks of the clinical trial and signed informed consent; 5) Eastern Cooperative Oncology Group (ECOG) score 0 or 1, expected survival of more than 3 months; and 6) there was no obvious myelosuppression at the time of enrollment: hemoglobin ≥9g/dl, neutrophils ≥1.5 × 10